MedTrace Logo

Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus

NCT00551590 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-10-04

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of the DPP-4 inhibitor sitagliptin on the incretin effect in patients with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Placebo tablet

placebo PO (placebo control for sitagliptin) for three days

DRUG

Sitagliptin tablet

Sitagliptin 100 mg PO for three days.

DRUG

Saline infusion

Saline IV (placebo control for exendin(9-39)) on two consecutive study days

DRUG

Exendin(9-39) infusion

Exendin(9-39) IV on two consecutive study days.

Sponsors & Collaborators

Principal Investigators

  • Joerg Schirra, MD · Clinical Research Unit, Dept. of Internal Medicine II, University of Munich

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-12-31
Completion
2011-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00551590 on ClinicalTrials.gov